Clinical Trial Update: Improved Post-Transplant Cyclophosphamide Regimens for Pediatric Patients With Refractory AML [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update describes improved post-transplant cyclophosphamide regimens for pediatric patients with refractory acute myeloid leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia in Pediatric Patients

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)

Snippet

Sponsor: Capital Research Institute of Pediatrics | Conditions: Hematopoietic System--Cancer | Phase 2 | Status: UNKNOWN